Ferrous Sulfate 325 MG tablet; NDC 33261-0715-00
Class I - DangerousWhat Should You Do?
- Check if you have this product: NDC 33261-0715-00 Batch ID: 57909-1, exp. date 04/30/2019 57909-2, exp. date 06/30/2019
- Do not eat it: Even if it looks and smells fine, do not consume this product.
- Throw it away or return it: You can return the product to the store for a full refund.
- Seek medical attention if needed: If you've consumed this product and feel unwell, contact your doctor immediately.
- Report problems: Report any issues to the FDA's Safety Reporting Portal.
⚠️ Emergency: If you experience severe symptoms after consuming this product, call 911 or Poison Control at 1-800-222-1222.
Recall Details
- Company:
- Aidarex Pharmaceuticals LLC
- Reason for Recall:
- Presence of Foreign Tablets/Capsules
- Classification:
- Class I - Dangerous
Dangerous or defective products that predictably could cause serious health problems or death.
- Status:
- terminated
Product Information
Full Description:
Ferrous Sulfate 325 MG tablet; NDC 33261-0715-00
Product Codes/Lot Numbers:
NDC 33261-0715-00 Batch ID: 57909-1, exp. date 04/30/2019 57909-2, exp. date 06/30/2019
Official Source
Always verify recall information with the official FDA source:
View on FDA.govFDA Recall Number: D-0810-2018
Related Recalls
Enalapril Maleate, USP 5MG, 30-count bottle, RX only. Packaged By: Aidarex Pharmaceuticals. Mfg: Wockhardt Ltd. India. NDC: 33261-0693-30
Aidarex Pharmaceuticals
Out-of-specification results for the Enalapril Diketopiperazine degradation product during commercial stability.
Enalapril Maleate, USP 2.5MG, 90-count bottle, RX only. Packaged By: Aidarex Pharmaceuticals. Mfg: Wockhardt Ltd. India. NDC: 33261-0977-90
Aidarex Pharmaceuticals
Out-of-specification results for the Enalapril Diketopiperazine degradation product during commercial stability.
Enalapril Maleate, USP 5MG, 90-count bottle, RX only. Packaged By: Aidarex Pharmaceuticals. Mfg: Wockhardt Ltd. India. NDC: 33261-0693-90
Aidarex Pharmaceuticals
Out-of-specification results for the Enalapril Diketopiperazine degradation product during commercial stability.